$AQST
Aquestive Therapeutics, Inc. Stock $aqst

$aqst Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000162828022012115 Filed on May 04, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$12.27M	$11.12M
YoY Change	10.32%	26.89%
Cost Of Revenue	$4.214M	$2.757M
YoY Change	52.85%	-24.65%
Gross Profit	$8.056M	$8.365M
YoY Change	-3.69%	63.83%
Gross Profit Margin	65.66%	75.21%
Selling, General & Admin	$13.02M	$13.23M
YoY Change	-1.59%	-9.46%
% of Gross Profit	161.63%	158.17%
Research & Development	$4.773M	$3.659M
YoY Change	30.45%	-15.96%
% of Gross Profit	59.25%	43.74%
Depreciation & Amortization	$714.0K	$743.0K
YoY Change	-3.9%	4.06%
% of Gross Profit	8.86%	8.88%
Operating Expenses	$17.79M	$16.89M
YoY Change	5.35%	-25.35%
Operating Profit	-$9.738M	-$8.525M
YoY Change	14.23%	-38.5%
Interest Expense	$1.618M	$2.761M
YoY Change	-41.4%	-0.36%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$13.22M	-$14.67M
YoY Change	-9.9%	-11.24%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$13.22M	-$14.67M
YoY Change	-9.9%	-11.24%
Net Earnings / Revenue	-107.74%	-131.92%
Basic Earnings Per Share	-$0.32	-$0.41
Diluted Earnings Per Share	-$0.32	-$0.41
COMMON SHARES
Basic Shares Outstanding	41.47M shares	35.56M shares
Diluted Shares Outstanding	41.47M shares	35.56M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$14.74M	$27.50M
YoY Change	-46.41%	-22.58%
Cash & Equivalents	$14.74M	$27.50M
Short-Term Investments
Other Short-Term Assets	$3.324M	$3.940M
YoY Change	-15.63%	34.01%
Inventory	$4.629M	$2.799M
Prepaid Expenses
Receivables	$19.90M	$10.21M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$42.59M	$44.44M
YoY Change	-4.18%	-13.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.496M	$6.279M
YoY Change	-28.4%	-30.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.886M	$7.835M
YoY Change	-12.11%	2620.49%
Total Long-Term Assets	$13.94M	$17.48M
YoY Change	-20.23%	30.46%
TOTAL ASSETS
Total Short-Term Assets	$42.59M	$44.44M
Total Long-Term Assets	$13.94M	$17.48M
Total Assets	$56.53M	$61.92M
YoY Change	-8.71%	-3.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.496M	$6.687M
YoY Change	27.05%	-34.97%
Accrued Expenses	$4.868M	$6.371M
YoY Change	-23.59%	47.48%
Deferred Revenue	$1.599M	$437.0K
YoY Change	265.9%	-34.09%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$6.563M	$3.860M
YoY Change	70.03%
Total Short-Term Liabilities	$24.18M	$20.05M
YoY Change	20.62%	30.52%
LONG-TERM LIABILITIES
Long-Term Debt	$47.68M	$34.19M
YoY Change	39.46%	-43.88%
Other Long-Term Liabilities	$1.862M	$1.761M
YoY Change	5.74%	-80.5%
Total Long-Term Liabilities	$1.862M	$1.761M
YoY Change	5.74%	-97.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.18M	$20.05M
Total Long-Term Liabilities	$1.862M	$1.761M
Total Liabilities	$149.7M	$113.7M
YoY Change	31.61%	33.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$270.0M	-$200.9M
YoY Change	34.38%	36.68%
Common Stock	$41.00K	$36.00K
YoY Change	13.89%	5.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$93.14M	-$51.80M
YoY Change
Total Liabilities & Shareholders Equity	$56.53M	$61.92M
YoY Change	-8.71%	-3.98%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$13.22M	-$14.67M
YoY Change	-9.9%	-11.24%
Depreciation, Depletion And Amortization	$714.0K	$743.0K
YoY Change	-3.9%	4.06%
Cash From Operating Activities	-$14.48M	-$14.10M
YoY Change	2.73%	3.37%
INVESTING ACTIVITIES
Capital Expenditures	$104.0K	$103.0K
YoY Change	0.97%	-21.37%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$104.0K	-$103.0K
YoY Change	0.97%	-21.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$9.891M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.298M	$9.891M
YoY Change	-86.88%	-26832.43%
NET CHANGE
Cash From Operating Activities	-$14.48M	-$14.10M
Cash From Investing Activities	-$104.0K	-$103.0K
Cash From Financing Activities	$1.298M	$9.891M
Net Change In Cash	-$13.29M	-$4.309M
YoY Change	208.38%	-68.79%
FREE CASH FLOW
Cash From Operating Activities	-$14.48M	-$14.10M
Capital Expenditures	$104.0K	$103.0K
Free Cash Flow	-$14.59M	-$14.20M
YoY Change	2.72%	3.14%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001398733
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-38599
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	Aquestive Therapeutics, Inc.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	30 Technology Drive
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Warren
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07059
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	941-1900
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3827296
CY2022Q1	dei	City Area Code CityAreaCode	908
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3324000	USD
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022Q1	dei	Trading Symbol TradingSymbol	AQST
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41912952	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14736000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28024000	USD
CY2022Q1	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	19896000	USD
CY2021Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	12120000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	4629000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	4038000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3077000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	42585000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	47259000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4496000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5055000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2524000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2725000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	38000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	51000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6886000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6903000	USD
CY2022Q1	us-gaap	Assets Assets	56529000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8736000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1599000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	765000	USD
CY2022Q1	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Current TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedCurrent	1732000	USD
CY2021Q4	us-gaap	Assets Assets	61993000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	8496000	USD
CY2021Q4	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Noncurrent TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent	59059000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8314000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4868000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	926000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	899000	USD
CY2021Q4	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Current TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedCurrent	1225000	USD
CY2022Q1	us-gaap	Loans Payable Current LoansPayableCurrent	6563000	USD
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent	2025000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	24184000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21964000	USD
CY2022Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	47680000	USD
CY2021Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	51551000	USD
CY2022Q1	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Noncurrent TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent	60346000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2485000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	7122000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1862000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	149672000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	144127000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1710000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1946000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	13890000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41620388	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41620388	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41228736	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41228736	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	41000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	41000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	176833000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	174621000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-270017000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-256796000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-93143000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-82134000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	56529000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61993000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12270000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11122000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4214000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2757000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4773000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3659000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13021000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13231000	USD
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	22008000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	19647000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9738000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8525000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	1618000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	2761000	USD
CY2022Q1	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	1861000	USD
CY2021Q1	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	3334000	USD
CY2022Q1	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	-3000	USD
CY2021Q1	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	-52000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13220000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14672000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13220000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-14672000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13220000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14672000	USD
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.41
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.41
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41465798	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41465798	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35563275	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35563275	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-82134000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1360000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts	-62000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	913000	USD
CY2022Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	0	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13220000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-93143000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-48497000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10197000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts	-306000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1507000	USD
CY2021Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	27000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-14672000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-51798000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13220000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-14672000	USD
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	727000	USD
CY2021Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	755000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	913000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1507000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	40000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1184000	USD
CY2022Q1	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	1836000	USD
CY2021Q1	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	3302000	USD
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	100000	USD
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-167000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	7678000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	3374000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	591000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	338000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	230000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	535000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	182000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-402000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3963000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2501000	USD
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	7602000	USD
CY2021Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	810000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14482000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14097000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	104000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	103000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-104000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-103000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1298000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	9891000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1298000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9891000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13288000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4309000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28024000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31807000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14736000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27498000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	1609000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	1610000	USD
CY2022Q1	aqst	Number Of Products Approved By Food And Drug Administration NumberOfProductsApprovedByFoodAndDrugAdministration	5	product
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14736000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-270017000	USD
CY2022Q1	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	1823000	USD
CY2021Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	3087000	USD
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	15489000	USD
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	7887000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12270000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11122000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12270000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11122000	USD
CY2022Q1	us-gaap	Accounts Receivable Gross AccountsReceivableGross	18619000	USD
CY2021Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	9678000	USD
CY2022Q1	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	1823000	USD
CY2021Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	3087000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2022Q1	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	506000	USD
CY2021Q4	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	605000	USD
CY2022Q1	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	19896000	USD
CY2021Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	12120000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	USD
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2021Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	605000	USD
CY2022Q1	aqst	Accounts Receivable Allowances Provision Reversal Related To Sales AccountsReceivableAllowancesProvisionReversalRelatedToSales	178000	USD
CY2022Q1	aqst	Accounts Receivable Allowances Credits And Payments AccountsReceivableAllowancesCreditsAndPayments	277000	USD
CY2022Q1	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	506000	USD
CY2022Q1	aqst	Accounts Receivable Allowances Provision Reversal Related To Sales AccountsReceivableAllowancesProvisionReversalRelatedToSales	178000	USD
CY2022Q1	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	506000	USD
CY2022Q1	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	2563000	USD
CY2021Q4	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	605000	USD
CY2021Q4	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	2224000	USD
CY2022Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1437000	USD
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1442000	USD
CY2022Q1	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	1192000	USD
CY2021Q4	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	1414000	USD
CY2022Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2000000	USD
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1182000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	4629000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	4038000	USD
CY2022Q1	aqst	Number Of Operating Leases NumberOfOperatingLeases	3	lease
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	45019000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	44915000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	40523000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	39860000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4496000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5055000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	714000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	743000	USD
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	419000	USD
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	96000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	433000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	119000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	972000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	944000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	565000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	565000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	424000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3470000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	834000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2636000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2867000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2867000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2829000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2816000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	38000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	51000	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	50000	USD
CY2022Q1	aqst	Cumulative Royalty Receivable CumulativeRoyaltyReceivable	6000000	USD
CY2021Q4	aqst	Cumulative Royalty Receivable CumulativeRoyaltyReceivable	6000000	USD
CY2022Q1	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	886000	USD
CY2021Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	903000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6886000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6903000	USD
CY2022Q1	aqst	Number Of Guaranteed Royalty Payments NumberOfGuaranteedRoyaltyPayments	8	Payment
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	198000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4868000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1600000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5965000	USD
CY2022Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	469000	USD
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	349000	USD
CY2022Q1	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	2563000	USD
CY2021Q4	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	2224000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	236000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8736000	USD
CY2019Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2000000	shares
CY2019Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2019Q3	aqst	Net Proceeds From Issuance Of Initial Notes Warrants And First Offer Rights NetProceedsFromIssuanceOfInitialNotesWarrantsAndFirstOfferRights	66082000	USD
CY2022Q1	aqst	Premiums Paid Early Retirement Of Debt PremiumsPaidEarlyRetirementOfDebt	2250000	USD
CY2020Q4	aqst	Premiums Paid Early Retirement Of Debt PremiumsPaidEarlyRetirementOfDebt	2250000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	18025000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	21888000	USD
CY2022Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	11587000	USD
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	51500000	USD
CY2021Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	13822000	USD
CY2021Q1	aqst	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	0	shares
CY2022Q1	aqst	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	0	shares
CY2022Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2909000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2021Q4	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	60284000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	50000	USD
CY2022Q1	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	1836000	USD
CY2022Q1	aqst	Liabilities Sale Of Future Royalties Current LiabilitiesSaleOfFutureRoyaltiesCurrent	1732000	USD
CY2022Q1	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	62078000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13220000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-14672000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41465798	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35563275	shares
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.41
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.41
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	913000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1507000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	913000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1507000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13220000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-14672000	USD
CY2016Q3	aqst	Number Of States In The Antitrust Litigation NumberOfStatesInTheAntitrustLitigation	41	state

Files In Submission

Name	View Source	Status
0001628280-22-012115-index-headers.html	Edgar Link	pending
0001628280-22-012115-index.html	Edgar Link	pending
0001628280-22-012115.txt	Edgar Link	pending
0001628280-22-012115-xbrl.zip	Edgar Link	pending
aqst-03312022ex311.htm	Edgar Link	pending
aqst-03312022ex312.htm	Edgar Link	pending
aqst-03312022ex321.htm	Edgar Link	pending
aqst-03312022ex322.htm	Edgar Link	pending
aqst-20220331.htm	Edgar Link	pending
aqst-20220331.xsd	Edgar Link	pending
aqst-20220331_cal.xml	Edgar Link	unprocessable
aqst-20220331_def.xml	Edgar Link	unprocessable
aqst-20220331_htm.xml	Edgar Link	completed
aqst-20220331_lab.xml	Edgar Link	unprocessable
aqst-20220331_pre.xml	Edgar Link	unprocessable
aquestivehaiscolicenseag.htm	Edgar Link	pending
aquestivehaiscolicenseag001.jpg	Edgar Link	pending
aquestivehaiscolicenseag002.jpg	Edgar Link	pending
aquestivehaiscolicenseag003.jpg	Edgar Link	pending
aquestivehaiscolicenseag004.jpg	Edgar Link	pending
aquestivehaiscolicenseag005.jpg	Edgar Link	pending
aquestivehaiscolicenseag006.jpg	Edgar Link	pending
aquestivehaiscolicenseag007.jpg	Edgar Link	pending
aquestivehaiscolicenseag008.jpg	Edgar Link	pending
aquestivehaiscolicenseag009.jpg	Edgar Link	pending
aquestivehaiscolicenseag010.jpg	Edgar Link	pending
aquestivehaiscolicenseag011.jpg	Edgar Link	pending
aquestivehaiscolicenseag012.jpg	Edgar Link	pending
aquestivehaiscolicenseag013.jpg	Edgar Link	pending
aquestivehaiscolicenseag014.jpg	Edgar Link	pending
aquestivehaiscolicenseag015.jpg	Edgar Link	pending
aquestivehaiscolicenseag016.jpg	Edgar Link	pending
aquestivehaiscolicenseag017.jpg	Edgar Link	pending
aquestivehaiscolicenseag018.jpg	Edgar Link	pending
aquestivehaiscolicenseag019.jpg	Edgar Link	pending
aquestivehaiscolicenseag020.jpg	Edgar Link	pending
aquestivehaiscolicenseag021.jpg	Edgar Link	pending
aquestivehaiscolicenseag022.jpg	Edgar Link	pending
aquestivehaiscolicenseag023.jpg	Edgar Link	pending
aquestivehaiscolicenseag024.jpg	Edgar Link	pending
aquestivehaiscolicenseag025.jpg	Edgar Link	pending
aquestivehaiscolicenseag026.jpg	Edgar Link	pending
aquestivehaiscolicenseag027.jpg	Edgar Link	pending
aquestivehaiscolicenseag028.jpg	Edgar Link	pending
aquestivehaiscolicenseag029.jpg	Edgar Link	pending
aquestivehaiscolicenseag030.jpg	Edgar Link	pending
aquestivehaiscolicenseag031.jpg	Edgar Link	pending
aquestivehaiscolicenseag032.jpg	Edgar Link	pending
aquestivehaiscolicenseag033.jpg	Edgar Link	pending
aquestivehaiscolicenseag034.jpg	Edgar Link	pending
aquestivehaiscolicenseag035.jpg	Edgar Link	pending
aquestivehaiscolicenseag036.jpg	Edgar Link	pending
aquestivehaiscolicenseag037.jpg	Edgar Link	pending
aquestivehaiscolicenseag038.jpg	Edgar Link	pending
aquestivehaiscolicenseag039.jpg	Edgar Link	pending
aquestivehaiscolicenseag040.jpg	Edgar Link	pending
aquestivehaiscolicenseag041.jpg	Edgar Link	pending
aquestivehaiscolicenseag042.jpg	Edgar Link	pending
aquestivehaiscolicenseag043.jpg	Edgar Link	pending
aquestivehaiscolicenseag044.jpg	Edgar Link	pending
aquestivehaiscolicenseag045.jpg	Edgar Link	pending
aquestivehaiscolicenseag046.jpg	Edgar Link	pending
aquestivehaiscolicenseag047.jpg	Edgar Link	pending
aquestivehaiscolicenseag048.jpg	Edgar Link	pending
aquestivehaiscolicenseag049.jpg	Edgar Link	pending
aquestivehaiscolicenseag050.jpg	Edgar Link	pending
aquestivehaiscolicenseag051.jpg	Edgar Link	pending
aquestivehaiscolicenseag052.jpg	Edgar Link	pending
aquestivehaiscolicenseag053.jpg	Edgar Link	pending
aquestivehaiscolicenseag054.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AQST
Aquestive Therapeutics, Inc. Stock $aqst

2022 Q1 Form 10-Q Financial Statement

#000162828022012115 Filed on May 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQST Aquestive Therapeutics, Inc. Stock $aqst

2022 Q1 Form 10-Q Financial Statement

#000162828022012115 Filed on May 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQST
Aquestive Therapeutics, Inc. Stock $aqst